First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial - Scorecard - MDSpire

First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial

  • By

  • Eusebio Luna Velasquez

  • Renil S. Titus

  • David-Dan Nguyen

  • Carlos Riveros

  • Aly-Khan Lalani

  • Dharam Kaushik

  • Guru P. Sonpavde

  • Petros Grivas

  • Christopher J. D. Wallis

  • Raj Satkunasivam

  • July 1, 2026

  • 0 min

Share

Clinical Scorecard: Comparison of First-Line Enfortumab Vedotin Combined with Pembrolizumab Versus Gemcitabine and Cisplatin in Patients with Metastatic Urothelial Carcinoma

At a Glance

CategoryDetail
ConditionMetastatic Urothelial Carcinoma
Key MechanismsEnfortumab vedotin and pembrolizumab demonstrate survival benefit as monotherapy; EV/P shows superior OS and PFS compared to platinum-based chemotherapy.
Target PopulationAdults (age ≥18 years) with metastatic urothelial carcinoma initiating first-line therapy.
Care SettingRetrospective cohort study using electronic health record data.

Key Highlights

  • EV/P approved as first-line regimen in 2024 based on superior OS and PFS.
  • Study utilized TriNetX database comprising over 140 health care organizations.
  • Outcomes may vary in routine practice compared to clinical trials.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of metastatic urothelial carcinoma confirmed using ICD-10 codes.

Management

  • First-line systemic therapy options include Enfortumab vedotin plus Pembrolizumab or Gemcitabine plus Cisplatin.

Monitoring & Follow-up

  • Monitor overall survival and time to next treatment as surrogate for progression-free survival.

Risks

  • Adverse events include peripheral neuropathy, hematologic toxic effects, gastrointestinal symptoms, and immune-related adverse events.

Patient & Prescribing Data

Adults with metastatic urothelial carcinoma initiating first-line therapy.

Observational data needed to assess effectiveness of EV/P in broader clinical settings.

Clinical Best Practices

  • Adjust for baseline demographics and comorbidities when evaluating treatment outcomes.
  • Utilize structured diagnostic codes for accurate patient characterization.

Related Resources & Content

Original Source(s)

First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial

  • by Eusebio Luna Velasquez, Renil S. Titus, David-Dan Nguyen, Carlos Riveros, Aly-Khan Lalani, Dharam Kaushik, Guru P. Sonpavde, Petros Grivas, Christopher J. D. Wallis, Raj Satkunasivam

  • July 1, 2026

Related Content

ASCO26: David Reardon, MD, Glioblastoma Vaccine

Dana-Farber Cancer Institute's Dr. David Reardon reports on data showing a phase 1 trial looking at a personalized vaccine plus pembrolizumab sparked tumor-targeting T cells in glioblastoma and was linked to longer survival in immune responders.

  • July 1, 2026

  • 1 min
Repurposing tricyclic drugs as cancer therapeutics: comparative analysis of antitumorigenic effects of chlorpromazine, amitriptyline and imipramine

ASCO26: Alicia Morgans, MD, MPH, ARACOG

Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.

  • July 1, 2026

  • 1 min